Sign in
ANVS Stock Price, Chart, Stats & News
Annovis Bio, Inc.
Save
32.46M
Market cap
–
Current P/E
–
Forward P/E
ANVS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -136.87% |
ROE | -159.43% |
D/E | – |
Interest coverage ratio | – |
ANVS valuation
P/E | – |
P/S | – |
P/B | 2.99x |
P/CF | -0.06x |
P/FCF | -0.05x |
P/OCF | -0.06x |
PEG | -0.84x |
EV multiple | -662.95x |
About
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions.
Similar securities
Based on sector and market capitalization
Report issue